Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Times cited: 4
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?.
Expert Opinion on Pharmacotherapy.
Times cited: 1
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
Times cited: 61
Myelodysplastic syndromes in the United States: An update for clinicians.
Annals of Medicine.
Times cited: 16